GENB compared with MCRB: revenue, margins and what each company keeps, and the suppliers and customers both name

GENBGenerate Biomedicines, Inc.

Mkt capRevenueRevenue

MCRBSeres Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

GENBGenerate Biomedicines, Inc.

MCRBSeres Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

GENB1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.14%—

MCRB2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±32.5%▲+6.63%×0.20

Q2 FY26±41.0%▼−4.67%×0.11

= impliedGENB realized, solidMCRB realized, hatchedOne scale, both sides: full bar = 42%× = |realized| ÷ impliedSource: market data

GENBGenerate Biomedicines, Inc.

13.05▲+3.82%· post 13.05

Mkt cap$1.7BRevenue$6MQ2 FY26

MCRBSeres Therapeutics, Inc.

2.02▼−3.13%· post 2.06

ClosedNov 6 '26

Mkt cap$20.2MRevenue$593,000Q3 FY26

Compare

ClosedNov 6 '26

GENBGenerate Biomedicines, Inc.

MCRBSeres Therapeutics, Inc.

13.05▲+3.82%post 13.05

Price

2.02▼−3.13%post 2.06

$1.7B

Mkt cap

$20.2M

Q2 FY26$6M

Revenue

$593,000Q3 FY26

GENB13.05▲+3.82%vsMCRB2.02▼−3.13%ClosedNov 6 '26